Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)

A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

Also Known As:

Networked: 347 relevant articles (17 outcomes, 24 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2.	Myelodysplastic Syndromes (Myelodysplastic Syndrome)
3.	Refractory Anemia with Excess of Blasts (RAEM)
4.	Refractory Anemia
5.	Leukemia

Experts

1.	Garcia-Manero, Guillermo: 11 articles (05/2014 - 04/2003)
2.	Kantarjian, Hagop: 10 articles (04/2014 - 06/2002)
3.	Ravandi, Farhad: 8 articles (04/2014 - 10/2006)
4.	Cortes, Jorge: 8 articles (04/2014 - 06/2003)
5.	O'Brien, Susan: 7 articles (04/2014 - 06/2003)
6.	Solary, Eric: 6 articles (05/2015 - 02/2008)
7.	Fenaux, Pierre: 6 articles (05/2015 - 01/2010)
8.	Jabbour, Elias: 6 articles (10/2014 - 10/2006)
9.	Gilliland, D Gary: 6 articles (11/2006 - 10/2002)
10.	Niscola, Pasquale: 5 articles (10/2015 - 04/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Myelomonocytic Leukemia:

1.	Etoposide (VP 16)FDA LinkGeneric 05/01/1994 - "Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis." 05/01/1979 - "[Successful therapy of chronic myelomonocytic leukemia with vp 16-213 (author's transl)]." 12/01/1993 - "A prior study showed that oral low-dose etoposide therapy was effective in patients with chronic myelomonocytic leukemia. " 09/01/2007 - "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide. " 12/01/1992 - "The case was diagnosed as chronic myelomonocytic leukemia and treated with oral etoposide (25mg/day). "
2.	Azacitidine (5 Azacytidine)FDA Link 11/01/2015 - "Next, a chronic myelomonocytic leukemia patient displayed complete lack of response despite several cycles of azacitidine. " 06/01/2014 - "[Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report]." 01/01/2014 - "Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach." 09/01/2013 - "In patients with myelodysplastic-type chronic myelomonocytic leukemia with a high number of blasts in bone marrow (≥ 10%), supportive therapy should be integrated with the use of 5-azacytidine. " 06/01/2013 - "Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine."
3.	imatinib (Gleevec)FDA Link 01/01/2008 - "Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13)." 05/01/2007 - "Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib." 04/01/2003 - "Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia." 01/01/2014 - "Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia." 08/01/2013 - "Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia."
4.	decitabine (5-aza-2'-deoxycytidine)FDA Link 04/01/2008 - "Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)." 04/01/2013 - "The current study analyzed the role of single nucleotide polymorphism array (SNP-A)-based karyotyping in prediction of clinical outcome in MDS or chronic myelomonocytic leukemia (CMML) patients following decitabine therapy. " 10/06/2011 - "Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial." 05/01/2015 - "Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia." 07/01/2011 - "[Treatment of two chronic myelomonocytic leukemia patients with Decitabine]."
5.	Cytarabine (Cytosar-U)FDA LinkGeneric 07/01/1993 - "Chromosomal analysis of the bone marrow revealed 45, XY, -7. He was diagnosed as chronic myelomonocytic leukemia (CMML), and treated with low-dose Ara-C. " 07/01/1987 - "Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia." 04/01/1987 - "[Successful treatment with low-dose Ara-C in a case of chronic myelomonocytic leukemia]." 01/01/1987 - "We conducted a phase II trial with low-dose Ara-C (5 mg/m2 per 12 h s.c.) and 13-CRA (60 mg/m2 per day orally) in 14 patients with MDS, six of whom had refractory anemia with excess of blasts (RAEB), seven had RAEB in transformation (RAEBt) and one chronic myelomonocytic leukemia (CMML). " 03/01/1988 - "Forty patients with high risk myelodysplastic syndromes--refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia--were treated with subcutaneous low dose cytosine arabinoside, 10 mg/m2 twice daily for up to 42 days. "
6.	Topotecan (Hycamtin)FDA LinkGeneric 10/01/1996 - "The aim of this study was to evaluate the activity of topotecan in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). " 10/01/1999 - "Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia." 11/01/1998 - "The activity of topotecan was evaluated in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). " 11/01/1998 - "Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia." 09/01/1998 - "Topotecan plus ara-C is equivalent to topotecan alone in chronic myelomonocytic leukemia (CMML), but significantly more effective in RAEB and RAEB-t. "
7.	Triptorelin (Trelstar)FDA Link 03/01/2006 - "This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer. "
8.	Gonadotropin-Releasing Hormone (GnRH)FDA Link 03/01/2006 - "This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer. "
9.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 03/01/2002 - "TEL/platelet-derived growth factor receptor beta (PDGF beta R) is the protein product of the t(5;12) translocation in chronic myelomonocytic leukemia. " 07/07/1998 - "In certain chronic myelomonocytic leukemias, a TEL/platelet-derived growth factor receptor beta (PDGFRbeta) fusion protein is produced as a consequence of the t(5;12) translocation. " 05/01/1998 - "The t(5;12) translocation identified in patients with chronic myelomonocytic leukemia (CMML) encodes a TEL/platelet-derived growth factor receptor beta (PDGFRbeta) fusion protein. " 01/01/2009 - "Fusion genes involving the platelet-derived growth factor receptor-beta (PDGFRbeta) are found in a subgroup of myeloproliferative neoplasms, with one such fusion, Tel/PDGFRbeta found in a subset of chronic myelomonocytic leukemia patients. " 04/22/1994 - "Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation."
10.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/01/1995 - "A patient with chronic myelomonocytic leukemia showed initial elevation of G-CSF with normalization after entering complete remission. " 03/01/2000 - "ACR (0.1 ng/ml) significantly increased the number of granulocyte colony-stimulating factor (G-CSF)-dependent colonies from circulating blast cells in vitro in six out of seven MDS patients with refractory anemia with excess of blast in transformation or chronic myelomonocytic leukemia, but not in all four patients with primary acute myelogenous leukemia. " 08/01/1997 - "In 7 children (5 with neuroblastoma IV, 1 with multifocal Ewing's sarcoma, and 1 with rhabdomyosarcoma IV), stem cells were mobilized by application of G-CSF at a dosage of 15-27.7 micrograms/kg body weight (median 16.25) subcutaneously following high-dose chemotherapy, according to the disease-related protocols, whereas 2 children had PBMNCS to induce graft vs. leukemia (GvL)-reaction in the HLA-identical sibling suffering from relapsed chronic myelogenous leukemia (CML: n = 1), or chronic myelomonocytic leukemia (CMML: n = 1) after allogeneic BMT. " 04/01/2005 - "However, approximately 15% of CN patients develop myeloid malignancies that have been associated with somatic mutations in the G-CSF receptor (G-CSFR) and RAS genes as well as with acquired monosomy 7. We report a CN patient with chronic myelomonocytic leukemia (CMML) who never received rh-G-CSF. " 07/01/2000 - "Six relapsed acute lymphoblastic leukemia (ALL), nine relapsed acute myeloblastic leukemia (AML), one chronic myelomonocytic leukemia (CMML) and one chronic myeloid leukemia (CML) in acute blast crisis between three to 18 years (median 10 years) received fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) chemotherapy (CT). "

Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation 12/01/2015 - "To analyze retrospectively the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML). " 02/01/2013 - "To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML). " 12/01/2015 - "[Clinical Analysis on Treatment of Chronic Myelomonocytic Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation]." 02/01/2013 - "[Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients]." 08/01/2014 - "This study was purposed to explore the therapeutic efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) and in patients with juvenile myelomonocytic leukemia (JMML). "
2.	Aftercare (After-Treatment) 07/01/1994 - "Chronic myelomonocytic leukemia (CMMol) developed in a 10-year-old girl after treatment of non-Hodgkin's lymphoma with a regimen which did not contain epipodophyllotoxins. " 09/01/1994 - "The diagnosis was acute myelomonocytic leukemia (M4, according to the French-American-British/FAB system of classification of acute leukemias) in eight cases, acute monocytic leukemia (M5) in four cases, aleukemic leukemia cutis as a recurrence of M2 leukemia after treatment in one case, and myelodysplastic syndrome in three cases, including one case of myelodysplasia with an excess of bone marrow blasts (RAEB-T) and two cases of chronic myelomonocytic leukemia, one of which presented as aleukemic leukemia cutis. " 07/01/2005 - "A unique case of a 72-year-old man with chronic myelomonocytic leukemia (CMML) who developed hepatic veno-occlusive disease (VOD) after treatment with a single dose of vincristine and standard doses of cytarabine is described. " 03/01/2006 - "This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer. "
3.	Transplantation (Transplant Recipients) 01/01/2006 - "About 40% of patients with chronic myelomonocytic leukemia survive in remission after transplantation. " 04/29/2010 - "We have previously shown that expression of oncogenic NRAS using a bone marrow transduction and transplantation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like disease in mice. " 11/01/2014 - "Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML, whereas transplantation remains a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia. " 06/01/2003 - "Diagnoses at transplantation were refractory anemia (RA) ( n=8), refractory anemia with excess of blasts (RAEB) ( n=6), RAEB in transformation (RAEB-T) ( n=13), chronic myelomonocytic leukemia (CMML) ( n=3), and sAML ( n=7). " 03/01/1987 - "A 41-year-old woman with chronic myelomonocytic leukemia received, as primary treatment, a novel preparatory regimen consisting of high dose fractionated total body irradiation and high dose VP-16 chemotherapy followed by allogeneic marrow transplantation from her histocompatible brother. "
4.	Radiotherapy 02/01/2013 - "Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization."
5.	Stem Cell Transplantation 09/01/2013 - "Both in myelodysplastic-type and myeloproliferative-type chronic myelomonocytic leukemia, allogeneic stem cell transplantation should be offered within clinical trials in selected patients." 05/01/2013 - "Chronic myelomonocytic leukemia (CMML) is a severe disease for which allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative treatment. " 05/01/2013 - "Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire." 06/01/2006 - "Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia." 05/01/2015 - "T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation."